PharmSource-M&A in the CMC Services Industry: Implications and Outlook

Region:Global

Author(s):

Product Code:GDPS0017MAR

Download Sample Report download
Buy the Full ReportStarting from $2995
Published on

April 2017

Total pages

36

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $2995

About the Report

About the Report

PharmSource-M&A in the CMC Services Industry: Implications and Outlook

Summary

M&A is reshaping the bio/pharmaceutical contract development services industry. Established CMOs and CROs are pursuing acquisitions to drive scale and broaden their offerings, while private equity are anxious to either gain a presence in the industry or cash in on investments already made. Acquisitions of facilities divested by bio/pharma companies offer an alternative route for entering the industry or increasing capacity.

Scope

According to the latest PharmSource Trend Report, M&A in the CMC Services Industry: Implications and Outlook, in the three-year period 2014-2016 there were 101 acquisitions of CMC services companies, including dose and API manufacturing, packaging, logistics, formulation and analytical services. Only 25% of the targets had revenues greater than $100 million; most targets were small companies. Contrary to the popular impression, little industry consolidation has resulted from M&A.

M&A in the CMC Services Industry: Implications and Outlook analyzes how M&A in the bio/pharma contract services industry is likely to play out over the next two years. It examines which capabilities are likely to be most in demand by acquirers and which companies are most likely to be targets.

Reasons to buy

CMOs: market trends, strategic planning, competitive intelligence, performance benchmarking

Bio/Pharma: supplier performance benchmarking, market trends, competitive intelligence

Private equity and Stock analysts: target identification and analysis, portfolio company performance benchmarking

Products

Table of Contents

Table of Contents

1 Table of Contents

Executive Summary

Objectives and Methodology

Overview of M&A Activity 2014-2016

Segment Close-Ups of M&A Activity 2014-1026

Valuations

Facility Acquisitions

What It Means

The Outlook for M&A in CMC Services

Appendix


List of Figure

1.2 List of Figures

Figure 1 Company Acquisitions 2014-2016 by Target Service Offering

Figure 2 Company Acquisitions 2014-2016 by Target Revenues

Figure 3 Company Acquisitions 2014-2016 by Target Ownership

Figure 4 Acquisition Targets by Sophistication of Capabilities

Figure 5 Number of Acquisitions by Buyer Rationale

Figure 6 Number of Acquisitions by Buyer's Core Business

Figure 7 Number of Acquisitions by Buyer Ownership

Figure 8 Number of Acquisitions by Principal Buyer Motivation

Figure 9 Dose Forms Manufactured by Acquired Dose Manufacturers

Figure 10 Bio/Pharma Facility Acquisitions 2014-2016


List of Table

1.1 List of Tables

Table 1 CMC Services Businesses Acquired as Part of Larger Deals

Table 2 Company Acquisitions 2014-2016 by Target Service and Size

Table 3 Company Acquisitions 2014-2016 by Target Service and Ownership

Table 4 Company Acquisitions 2014-2016 by Target Market Scope and Size

Table 5 Most Active Acquirers 2014-2016

Table 6 Acquisitions of Dose Manufacturers

Table 7 Acquisitions of Biologics API Manufacturers

Table 8 Acquisitions of Small Molecule API Manufacturers

Table 9 Acquisitions of Analytical Services Providers

Table 10 Acquisitions of Formulation and CTM Providers

Table 11 Acquisitions of Packaging and Logistics Services Providers

Table 12 CMC Services Deals with Known Transaction Value and Multiples

Table 13 Facility Acquisitions by CMOs 2014-2016

Table 14 Number of Deals by Buyer and Target Service Offering

Table 15 Acquisitions by Private Equity Firms 2014-16

Table 16 Service Providers Owned 4+ Years by PE Firms

Table 17 Potential Targets: Biologics API Service Providers

Table 18 Potential Targets: Gene and Cell Therapy Providers

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022